Literature DB >> 24625502

A comparison of intense pulsed light and laser treatment of telangiectases in patients with systemic sclerosis: a within-subject randomized trial.

Graham Dinsdale1, Andrea Murray1, Tonia Moore2, Janice Ferguson2, Jack Wilkinson2, Helen Richards2, Christopher E M Griffiths2, Ariane L Herrick3.   

Abstract

OBJECTIVE: Cutaneous telangiectases are a characteristic and psychologically distressing feature of SSc. Our aim was to assess the efficacy of two light-based treatments: pulsed dye laser (PDL) and intense pulsed light (IPL).
METHODS: Nineteen patients with facial or upper limb telangiectases underwent three treatments with PDL and IPL (randomly assigned to left- and right-sided lesions). Outcome measures were clinical photography (assessed by two clinicians), dermoscopy (assessed by two observers), laser Doppler imaging (LDI) and observer and patient opinion, including patient self-assessment psychological questionnaires [Hospital Anxiety and Depression Scale (HADS), Adapted Satisfaction with Appearance Scale (ASWAP)].
RESULTS: Comparison between 16-week follow-up and baseline photography scores (from -2 to +2 on a Likert scale, with >0 being improvement) were a mean score for PDL of 1.7 (95% CI 1.4, 2.0) and for IPL 1.4 (0.9, 1.8), with a mean difference between PDL and IPL of -0.3 (-0.5, -0.1) (P = 0.01). Dermoscopy scores also improved with both therapies: PDL 1.3 (1.1, 1.5) and IPL 0.8 (0.5, 1.1), again greater with PDL (P = 0.01). LDI showed decreases in blood flow at 16 weeks, indicating a response to both therapies. All patients reported benefit from treatment (more preferred PDL at 16 weeks). Psychological questionnaires also indicated improvement after therapy with mean change in ASWAP of -13.9 (95% CI -20.5, -7.4). No side effects were reported for IPL; PDL caused transient bruising in most cases.
CONCLUSION: Both PDL and IPL are effective treatments for SSc-related telangiectases. Outcome measures indicate that PDL has better outcomes in terms of appearance, although IPL had fewer side effects.
© The Author 2014. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  intense pulsed light; laser; systemic sclerosis; telangiectases; treatment

Mesh:

Year:  2014        PMID: 24625502     DOI: 10.1093/rheumatology/keu006

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  7 in total

Review 1.  Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.

Authors:  Caterina Ferreli; Giulia Gasparini; Aurora Parodi; Emanuele Cozzani; Franco Rongioletti; Laura Atzori
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

2.  Dermoscopy Update: Review of Its Extradiagnostic and Expanding Indications and Future Prospects.

Authors:  Sidharth Sonthalia; Paola Pasquali; Mahima Agrawal; Poonam Sharma; Abhijeet K Jha; Enzo Errichetti; Aimilios Lallas; Virendra N Sehgal
Journal:  Dermatol Pract Concept       Date:  2019-10-31

Review 3.  Patient-reported outcome instruments in clinical trials of systemic sclerosis.

Authors:  John D Pauling; Joana Caetano; Corrado Campochiaro; Giacomo De Luca; Ana Maria Gheorghiu; Maria Grazia Lazzaroni; Dinesh Khanna
Journal:  J Scleroderma Relat Disord       Date:  2019-11-25

Review 4.  Treatment for telangiectasias and reticular veins.

Authors:  Luis Cu Nakano; Daniel G Cacione; Jose Cc Baptista-Silva; Ronald Lg Flumignan
Journal:  Cochrane Database Syst Rev       Date:  2021-10-12

5.  Orofacial manifestations of systemic sclerosis.

Authors:  B J Veale; R Y Jablonski; T M Frech; J D Pauling
Journal:  Br Dent J       Date:  2016-09-23       Impact factor: 1.626

Review 6.  Management of Endothelial Dysfunction in Systemic Sclerosis: Current and Developing Strategies.

Authors:  Djúlio César Zanin-Silva; Maynara Santana-Gonçalves; Marianna Yumi Kawashima-Vasconcelos; Maria Carolina Oliveira
Journal:  Front Med (Lausanne)       Date:  2021-12-22

Review 7.  Emerging treatments for scleroderma/systemic sclerosis.

Authors:  Jane L Zhu; Samantha M Black; Henry W Chen; Heidi T Jacobe
Journal:  Fac Rev       Date:  2021-05-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.